Prevention of bone mineral density loss in patients with rheumatoid arthritis treated with anti-TNFalpha therapy.
This review focuses on recent advances in the effect of anti-TNFalpha therapy on bone metabolism and bone mineral density (BMD) in rheumatoid arthritis (RA). RA is a chronic disease characterized by inflammation of the synovial joint, cartilage degradation, and subsequent bone destruction. Bone damage is often manifested as erosions, localized juxta-articular bone loss, or generalized bone loss. Thus, blockade of TNFa not only serves to block inflammation, but also halts the erosive nature of RA and generalized/localized juxta-articular bone loss. Here, we review recent findings showing that anti-TNFa therapy is also effective on halting systemic bone loss. In vitro, TNFa reduces osteoblast activity and increases osteoclast activity through RANKL-RANK pathway. In arthritis animal models, an imbalance between bone formation and resorption is observed. In humans, this coupling of destruction is restored by anti-TNFalpha therapy early on, but only for a few months. Thus, anti-TNFalpha prevents the BMD loss in RA patients. In summary, TNFa blockade is not only able to prevent joint destruction, but it is also able to prevent bone loss in RA patients. Future studies are needed to address if TNFa blockers have an effect on bone fractures.
Marotte
Hubert
H
Clinical Immunology Unit, Departments of Immunology and Rheumatology, University of Lyon, and Unité Mixte Hospices Civils de Lyon-bioMérieux, Hôpital Edouard Hérriot, Lyon, France.
Miossec
Pierre
P
Ann Rheum Dis. 2005 Feb;64(2):336-7
15647447
Inflammation. 1992 Dec;16(6):587-601
1459694
Bone. 1999 Apr;24(4):381-5
10221550
Biochem Biophys Res Commun. 1998 Sep 29;250(3):776-81
9784422
Genes Dev. 1998 May 1;12(9):1260-8
9573043
Ann N Y Acad Sci. 2002 Jun;966:502-7
12114311
Arthritis Rheum. 2001 Jun;44(6):1254-60
11407683
J Biol Chem. 1997 Mar 28;272(13):8109-12
9079619
J Biol Chem. 1998 Jun 5;273(23):14363-7
9603945
J Clin Invest. 2002 Nov;110(10):1419-27
12438440
Br J Rheumatol. 1997 Jun;36(6):643-50
9236673
J Bone Miner Res. 1993 Jun;8(6):659-68
8328307
Bone. 2000 Apr;26(4):367-73
10719280
N Engl J Med. 1999 Jan 28;340(4):253-9
9920948
Am J Pathol. 2002 Oct;161(4):1419-27
12368214
Osteoporos Int. 2001;12(2):117-23
11303711
Ann Rheum Dis. 2006 Nov;65(11):1495-9
16606653
Curr Opin Rheumatol. 2004 Jul;16(4):428-34
15201607
Arthritis Rheum. 2001 Feb;44(2):253-9
11229454
J Bone Miner Metab. 2001;19(2):76-83
11281163
Rheumatol Int. 1984;4(1):1-8
6718949
N Engl J Med. 2006 Feb 23;354(8):821-31
16495394
J Clin Invest. 2003 Mar;111(6):821-31
12639988
J Rheumatol. 2003 Dec;30(12):2590-6
14719199
Ann Rheum Dis. 2001 May;60(5):521-2
11302878
Rheumatology (Oxford). 2005 Dec;44(12):1546-8
16263785
Arthritis Rheum. 2004 May;50(5):1400-11
15146409
Lymphokine Cytokine Res. 1991 Apr;10(1-2):15-21
1873357
Arthritis Rheum. 2005 Apr;52(4):1020-30
15818697
Arthritis Rheum. 2005 Aug;52(8):2307-12
16052586
Bone. 2002 Feb;30(2):428-35
11856653
Arthritis Rheum. 2002 Jun;46(6):1443-50
12115173
Arthritis Rheum. 2003 Oct;48(10):2996-7
14558111
Ann Rheum Dis. 2008 Jun;67(6):823-8
17644545
Arthritis Rheum. 2002 Mar;46(3):785-92
11920416
Ann Rheum Dis. 2008 Mar;67(3):353-7
17644538
Am J Pathol. 2001 Nov;159(5):1689-99
11696430
Rheumatology (Oxford). 2006 Jun;45(6):761-4
16436492
Ann Rheum Dis. 1995 Jan;54(1):49-52
7880122
Biochem Biophys Res Commun. 2000 Sep 7;275(3):768-75
10973797
J Bone Miner Res. 2000 Jul;15(7):1321-9
10893680
Arthritis Rheum. 2002 Jul;46(7):1744-53
12124857
Arthritis Res. 2000;2(1):33-7
11094416
Bone. 2004 Nov;35(5):1200-7
15542046
Arthritis Rheum. 2000 Oct;43(10):2178-88
11037877
Arthritis Rheum. 1993 Nov;36(11):1510-6
8240428
J Immunol. 1999 Aug 1;163(3):1521-8
10415055
J Bone Miner Res. 1996 Jun;11(6):707-30
8725168
Ann Rheum Dis. 1993 Jan;52(1):21-6
8427509
Best Pract Res Clin Rheumatol. 2001 Mar;15(1):105-23
11358418
Nature. 1999 Nov 18;402(6759):304-9
10580503
Arthritis Rheum. 2002 Jul;46(7):1720-8
12124854
J Bone Miner Res. 2003 May;18(5):859-67
12733725
Arthritis Rheum. 2006 Oct;54(10):3104-12
17009229
J Biol Chem. 2002 Jan 25;277(4):2695-701
11723115
Bone. 1997 Jul;21(1):17-21
9213003
Br J Rheumatol. 1994 Mar;33(3):224-30
8156283
Blood. 1998 May 15;91(10):3574-81
9572991
Best Pract Res Clin Rheumatol. 2003 Oct;17(5):729-52
12915155
Rev Rhum Engl Ed. 1997 Mar;64(3):153-9
9090763
Endocrinology. 2000 Nov;141(11):3956-64
11089525
J Clin Invest. 2000 Nov;106(10):1229-37
11086024
Nature. 1986 Feb 6-12;319(6053):516-8
3511389
Br J Rheumatol. 1994 Jun;33(6):541-5
8205401
Lancet. 1994 Jul 2;344(8914):23-7
7912297
Ann Rheum Dis. 2004 Jan;63(1):15-22
14672886
Clin Exp Rheumatol. 2000 Nov-Dec;18(6):683-90
11138329
Z Rheumatol. 2000;59 Suppl 1:33-8
10769433
J Exp Med. 2000 Aug 21;192(4):463-74
10952716
Arthritis Rheum. 2000 Feb;43(2):250-8
10693863
J Immunol. 1999 Nov 1;163(9):5049-55
10528210
Endocrinology. 1997 Sep;138(9):3849-58
9275074
J Clin Invest. 1997 Apr 1;99(7):1699-703
9120014
J Biol Chem. 2001 Jun 8;276(23):20659-72
11274143
J Bone Miner Res. 1999 Sep;14(9):1478-85
10469275
Lancet. 1999 Dec 4;354(9194):1932-9
10622295
Am J Pathol. 1998 Apr;152(4):943-51
9546355
Ann Rheum Dis. 2002 Nov;61 Suppl 2:ii84-6
12379632
J Bone Miner Res. 1998 May;13(5):793-802
9610743
Osteoporos Int. 1993;3 Suppl 1:106-7
8461533
Ann Rheum Dis. 1995 Oct;54(10):801-6
7492217
Arthritis Res Ther. 2005;7(1):R149-55
15642135
Am J Gastroenterol. 2005 Sep;100(9):2031-5
16128948
J Bone Miner Res. 2001 Feb;16(2):348-60
11204435
Arthritis Res Ther. 2007;9(3):R61
17597527
BMJ. 1993 Feb 27;306(6877):558
8461772
Immunol Today. 2000 Oct;21(10):495-502
11071528
Ann Rheum Dis. 2005 Aug;64(8):1137-40
15642695
Arthritis Rheum. 2000 Nov;43(11):2523-30
11083276
J Rheumatol. 1999 Jun;26(6):1250-6
10381038
Arthritis Rheum. 2000 Feb;43(2):259-69
10693864
N Engl J Med. 2000 Nov 30;343(22):1594-602
11096166
Arthritis Rheum. 1987 Jul;30(7):721-8
3619959
Ann Rheum Dis. 2003 Apr;62(4):347-9
12634235